Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06380751
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-03-25
Brief Title:
Saruparib AZD5305 Plus Camizestrant Compared With CDK46 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive HER2-Negative IHC 0 1 2 ISH Non-amplified BRCA1 BRCA2 or PALB2m Advanced Breast Cancer
Sponsor:
Organization:
AstraZeneca
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
500
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: